ivermectin oral / Generic mfg. 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12...5859606162636465666768...129130»
  • ||||||||||  monepantel (PAA1) / Pharmaust
    Clinical, Journal:  First case of monepantel resistant nematodes of sheep in Sweden. (Pubmed Central) -  Nov 5, 2021   
    Anthelmintic resistance was also confirmed on two occasions to different compounds of ivermectin and once to albendazole, but not to levamisole which was tested twice. In conclusion, this is the first description of triple resistance to AH drugs in GIN of sheep in Sweden.
  • ||||||||||  ivermectin oral / Generic mfg., ivermectin topical / Generic mfg.
    [VIRTUAL] LIVER INJURY IN THE SETTING OF IVERMECTIN PROPHYLAXIS FOR COVID-19 INFECTION () -  Nov 2, 2021 - Abstract #AASLD2021AASLD_2408;    
    Additionally, this case supports the idea that Ivermectin use can result in serious hepatocellular injury. Thus, it should be used with caution if the drug is taken over-the-counter without a prescription.
  • ||||||||||  hydroxychloroquine / Generic mfg., methotrexate IV / Generic mfg.
    EARLY DIAGNOSIS OF EOSINOPHILIC FASCIITIS IN A 16 YEAR-OLD FEMALE (Hall B (1st Floor); Monitor 08) -  Nov 2, 2021 - Abstract #ACAAI2021ACAAI_893;    
    Infectious work-up revealed positive Toxocara IgG levels, which prompted albendazole treatment...This vaccine could have triggered an inflammatory process in the patient’s already hyper-reactive immune system. It is important to promptly recognize EF, as prolonged symptoms prior to diagnosis is associated with a poor treatment response.
  • ||||||||||  ivermectin oral / Generic mfg., doxycycline delayed-release / Generic mfg.
    Phase classification, Combination therapy:  Trial of Combination Therapy to Treat COVID-19 Infection (clinicaltrials.gov) -  Nov 2, 2021   
    P1,  N=31, Active, not recruiting, 
    It is important to promptly recognize EF, as prolonged symptoms prior to diagnosis is associated with a poor treatment response. Phase classification: P2 --> P1
  • ||||||||||  ivermectin oral / Generic mfg.
    Clinical, Journal:  Intervention protocol to improve scabies control in enclosed communities: a case report. (Pubmed Central) -  Oct 30, 2021   
    Our study lies within the idea of discovering repurposing drugs as inhibitors against the different types of human cancers by targeting essential pathways in order to accelerate the drug development cycle. The high incidence of scabies cases detected in prison led us to carry out a bibliographic review that brought about changes in the treatment protocol that may be of interest for the control of the disease in closed communities.
  • ||||||||||  ivermectin oral / Generic mfg., albendazole / Generic mfg.
    Clinical, Journal:  Case report: Control of intestinal nematodes in captive Chlorocebus sabaeus. (Pubmed Central) -  Oct 30, 2021   
    Although initially being cleared of Capillaria following treatment, three AGMs were found to be infected at the end of the study. The ivermectin and albendazole treatment regimen coupled with good husbandry practices to prevent reinfections effectively controlled nematode infections in captive AGMs.
  • ||||||||||  mebendazole / Generic mfg., albendazole / Generic mfg.
    Journal:  Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update. (Pubmed Central) -  Oct 30, 2021   
    Two clinical reports for albendazole and 2 case reports for mebendazole have revealed promising effects of these drugs in human patients having variable types of cancers. However, because of the toxicity of albendazole, for example, neutropenia due to myelosuppression, if high doses are used for a prolonged time, mebendazole is currently more popularly used than albendazole in anti-cancer clinical trials.
  • ||||||||||  ivermectin oral / Generic mfg.
    Clinical, Journal:  Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial. (Pubmed Central) -  Oct 29, 2021   
    However, because of the toxicity of albendazole, for example, neutropenia due to myelosuppression, if high doses are used for a prolonged time, mebendazole is currently more popularly used than albendazole in anti-cancer clinical trials. In patients with mild and moderate COVID-19, a single oral administration of Ivermectin did not significantly increase either the negativity of RT-PCR or decline in viral load at day 5 of enrolment compared with placebo.
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  Microscopic interactions between ivermectin and key human and viral proteins involved in SARS-CoV-2 infection. (Pubmed Central) -  Oct 28, 2021   
    The drug/target interactions have been characterized in silico by describing the nature of the non-covalent interactions found and by measuring the extent of their time duration along the MD simulation. Results reveal that the ACE2 protein and the ACE2/RBD aggregates form the most persistent interactions with ivermectin, while the binding with the remaining viral proteins is more limited and unspecific.
  • ||||||||||  imatinib / Generic mfg., ivermectin oral / Generic mfg.
    [VIRTUAL] COVID-19 IN CHRONIC MYELOID LEUKEMIA PATIENTS – BRAZILIAN EXPERIENCE () -  Oct 27, 2021 - Abstract #HEMO2021HEMO_597;    
    Male patients were predominant (60%). The median time of CML diagnosis was 9 years (0-29). Most of the pts were in first line therapy (57.5%), 27% in second line and 11% in third line. Current CML treatment at COVID-19 was: imatinib (46.5%), nilotinib (22%), dasatinib (16%), post-transplant (4%), asciminib (1%), ponatinib (1%), treatment -free remission (2%), in treatment (7%). COVID-19 grade: asymptomatic (4%), mild (66%), moderate (12%), severe/critical (16%). CML status at COVID: AP/BC (3%), CP (12.4%), hematologic response (11%), complete cytogenetic response (4%), MMR (34%), MR4.0 (8%), MR4.5 (27%). Eleven patients interrupted treatment temporarily during COVID. COVID-19 was confirmed by RT-PCR of oral and nasal swab collection (68%) or rapid/serologic test (32%). Comorbidities were present in 34 pts, most common were: hypertension (33%), diabetes (14%), chronic renal failure (4%), chronic obstructive pulmonary disease/emphysema (5.5%), pulmonary hypertension (1). Hospitalization occurred in 30% of the cases, 18% in an intensive care unit, 8% with mechanical ventilation. Treatment received for COVID-19: antibiotics (31%), steroids (16%), chloroquine (5.5%), oseltamivir (4%); ivermectin (8%): ​​heparin (3%). Sixty-nine patients recovered, 4 died from COVID-19 (5.4%): one 42-year old newly diagnosed male patient with high leukocyte counts and a simultaneous bacterial infection, two 70-year old patients treated with imatinib, both in MR4.5, and one 31-year old male patient treated with nilotinib, after imatinib and dasatinib failure, with hematologic response. A fifth patient in the accelerated phase died 2 months after discharge, from disease progression and pulmonary infection. All cases occurred before vaccination. There was one case of re-infection, in a patient treated with imatinib. Discussion : Conclusion s the majority of COVID-19 cases in the CML population was mild, but there were 2 deaths of young patients with active disease and two deaths in elderly patients , one of them with comorbidities. The mortality in CML was lower than observed in other hematologic cancers.
  • ||||||||||  ivermectin oral / Generic mfg., meropenem / Generic mfg.
    [VIRTUAL] ACUTE HEMATOLOGICAL MANIFESTATIONS OF VISCERAL LEISHMANIASIS WITH MEDULAR INFILTRATION: CASE REPORT () -  Oct 27, 2021 - Abstract #HEMO2021HEMO_33;    
    Objective To report a case of visceral leishmaniasis with reactional plasmacytosis and a monoclonal peak associated with leishmania in myelogram. He appeared at the emergency service of the Hospital Universitário de Santa Maria on March 22, 2021, due to mental confusion, difficulty in walking and loss of strength in the left upper limb, which started 2 months ago and has recently worsened, associated with weight loss. 10 kg. She was febrile, with speech difficulties and fecal incontinence. Laboratory with anemia (hemoglobin 7.3, VCM 75.3, CHCM 33.2), leukopenia (1190 leukocytes), thrombocytopenia (54 thousand platelets), serum iron 19 ug/dL (VR 50-175 ug/dL), total iron fixation capacity 68 ug/dL (VR 250-450), ferritin 1442 ng/mL (VR 30-400 ng/mL), folic acid > 20 ng/mL (VR 4.6-34.8 ng/mL) and vitamin B12 627.50 pg/mL (VR 191-771 pg/ml). Abdominal tomography showed hepatomegaly of 17 cm and splenomegaly of 22 cm. Requested evaluation of the hematology team for pancytopenia and hepatosplenomegaly. Protein electrophoresis with monoclonal gamma globulin peak, corresponding to 49.30% of the total, myelogram showed hypercellular bone marrow with 40% plasmacytosis and the presence of rare reticular cells with phagocytosed leishmania. Immunophenotyping for plasma cell evaluation showed 5.6% polyclonal plasma cell cells without aberrant expression, with CD18/CD38, CD45/CD19+ phenotype and preserved kappa/lambda ratio. 46XY normal karyotype. Rapid test for leishmaniasis positive by immunochromatography on April 7, starting treatment with Amphotericin B 500 mg IV, associated with Meropenem 1 g IV, Ivermectin 12 mg VO and Albendazol 400 mg VO. During hospitalization, the patient progresses with worsening renal function associated with multiple organ dysfunctions and death.Discussion and Conclusion Visceral leishmaniasis is a protozoal infestation that can manifest with hepatosplenomegaly, fever, lymphadenopathy, pancytopenia and hypergammaglobulinemia - similar to the case described. With regard to bone marrow findings, the literature reports erythroid hyperplasia, increase in plasma cells and intracellular parasites (amastigote form) in mononuclear phagocytes. Among the changes observed in the red series, anemia originates from a combination of factors, including splenic sequestration, blockage of production in the marrow, hemolysis, hemolysis, immune mechanisms, concomitant infections (intestinal parasites such as ascariasis and hookworm) and nutritional deficiency (mainly iron deficiency). Still, regarding the white series, leukopenia and neutropenia lower than 1,500/mm3 are found with great frequency in patients infected with L. chagasi, and the absolute count of lymphocytes and monocytes is usually low. A high degree of suspicion of leishmaniasis must be maintained by hematologists and included in the differential diagnosis of patients who present the described clinic, particularly in geographical areas where the disease is endemic, such as Brazil.
  • ||||||||||  ivermectin oral / Generic mfg., doxycycline delayed-release / Generic mfg.
    Enrollment closed, Combination therapy:  Trial of Combination Therapy to Treat COVID-19 Infection (clinicaltrials.gov) -  Oct 27, 2021   
    P2,  N=31, Active, not recruiting, 
    Infectious complications motivated hospitalizations. Recruiting --> Active, not recruiting